SCHEMBL7947398

SCHEMBL7947398

CN(C)S(=O)(=O)Nc1cncc(-c2cc3ccccc3n2C)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.47
PIK3C3 Q8NEB9 1/20 0.46
CYP11B2 P19099 2/20 0.43
APP P05067 4/20 0.43
CHRNB1 P11230 1/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNB3 Q05901 1/20 0.42
PTGES2 Q9H7Z7 1/20 0.42
PRMT6 Q96LA8 2/20 0.41
BRD4 O60885 1/20 0.41
ADRA2A P08913 1/20 0.39
MEN1 O00255 1/20 0.38
PIK3CB P42338 1/20 0.38
ALDH1A1 P00352 1/20 0.38
PIK3CA P42336 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1605395 0.87 CYP11B2 (0.45) KMT2ACYP11B2APPCHRNB1CHRNB2
SCHEMBL1606596 0.86 KMT2A (0.50) KMT2ACYP11B2APPCHRNB1CHRNB2
SCHEMBL1606665 0.84 CYP11B2 (0.59) KMT2ACYP11B2APPCHRNB1CHRNB2
SCHEMBL1605287 0.81 CYP11B2 (0.48) KMT2ACYP11B2APPCHRNB1CHRNB2
SCHEMBL1605477 0.79 CYP11B2 (0.46) KMT2ACYP11B2APPCHRNB1CHRNB2
SCHEMBL27957055 0.78 KMT2A (0.46) KMT2ACYP11B2APPCHRNB1CHRNB2
SCHEMBL1605950 0.78 CYP11B2 (0.59) KMT2ACYP11B2APPCHRNB1CHRNB2
SCHEMBL1606222 0.75 KMT2A (0.46) KMT2ACYP11B2APPCHRNB1CHRNB2
SCHEMBL1607150 0.75 CYP11B2 (0.43) KMT2ACYP11B2APPCHRNB1CHRNB2
SCHEMBL1606956 0.74 USP2 (0.47) KMT2ACYP11B2APPCHRNB1CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242963-B2 Organic compounds NOVARTIS AG (CH) 2016-01-26 US disclosed
US-20150210672-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2015-07-30 US disclosed
US-20140288126-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2014-09-25 US disclosed
US-8791141-B2 Organic compounds NOVARTIS AG (CH) 2014-07-29 US disclosed
US-8030334-B2 Organic compounds NOVARTIS AG (CH) 2011-10-04 US disclosed
US-8030334-B2 Organic compounds NOVARTIS AG (CH) 2011-10-04 US disclosed
US-20110082129-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-04-07 US disclosed
US-20100261698-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-10-14 US disclosed
US-20100261698-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-10-14 US disclosed
WO-2009156462-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082129-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 KMT2A 4447/4885PIK3C3 1662/4885CYP11B2 13/4885
US-20100261698-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 KMT2A 4447/4885PIK3C3 1662/4885CYP11B2 13/4885
US-20150210672-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 KMT2A 4274/4885PIK3C3 1991/4885CYP11B2 12/4885
US-20140288126-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 KMT2A 4274/4885PIK3C3 1991/4885CYP11B2 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.